Subcutaneous methotrexate in patients with moderate to severe psoriasis: a critical appraisal.

CONCLUSIONS: Warren et al conclude that the 52-week risk-benefit profile of subcutaneous methotrexate is favourable in patients with psoriasis. This article is protected by copyright. All rights reserved. PMID: 29399784 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research